Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ankylosing Spondylitis Clear all
Active, not recruiting No phase listed Observational

Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries

NCT02281747
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
20 Years to 100 Years
Enrollment
521,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

NCT02159053
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Anniston, Alabama • Upland, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jun 10, 2026, 7:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jun 10, 2026, 7:32 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

OTIS Cimzia Pregnancy Registry

NCT01797224
View directory record Official record
Conditions
Crohn's Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Female only
Enrollment
925 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

NCT01061723
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jun 10, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional

ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis

NCT04795141
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
ABY-035, Placebo
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Glendale, Arizona • Canoga Park, California • Huntington Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

NCT02696798
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

NCT01786668
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

NCT03215277
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab, Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

NCT03357471
View directory record Official record
Conditions
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
Interventions
e-Device
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Jun 10, 2026, 7:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

NCT02696785
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

NCT01109940
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457A
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Jun 10, 2026, 7:32 PM EDT
Withdrawn Phase 2 Interventional

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

NCT02429882
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Brodalumab 210 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Scottsdale, Arizona • Oklahoma City, Oklahoma • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Jun 10, 2026, 7:32 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Novel Quantitative MRI for Axial Spondyloarthritis

NCT03778515
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
MRI
Diagnostic Test
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

NCT03350815
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
150 mg open-label secukinumab, 150 mg double-blinded secukinumab, 300 mg double-blinded secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
65
States / cities
Jonesboro, Arkansas • Fullerton, California • Loma Linda, California + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Jun 10, 2026, 7:32 PM EDT
Active, not recruiting Not applicable Interventional

Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity

NCT05715463
View directory record Official record
Conditions
Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases
Interventions
Resource sheets, Community Resource Specialist, Nurse Navigator
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis

NCT03355573
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Sarasota, Florida • Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Jun 10, 2026, 7:32 PM EDT
Terminated Phase 2 Interventional Results available

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

NCT04947579
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
CC-99677, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
16
States / cities
Flagstaff, Arizona • Gilbert, Arizona • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Jun 10, 2026, 7:32 PM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Jun 10, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jun 10, 2026, 7:32 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Chronic Pain, Couples, & Physical Activity

NCT04077164
View directory record Official record
Conditions
Chronic Pain, Fibromyalgia, Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Chronic Low-back Pain, Chronic Shoulder Pain
Interventions
No intervention, observational only.
Other
Lead sponsor
Illinois Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 10, 2026, 7:32 PM EDT
Not yet recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jun 10, 2026, 7:32 PM EDT